ROCKVILLE, Md.--(BUSINESS WIRE)--Tomorrow, Immunomic Therapeutics, Inc. scientist, Dr. Pratima Sinha, will present at the 3rd Annual International Conference on Vaccine Research and Development. Dr. Sinha will discuss her research employing LAMP technology in hopes of enhancing antitumor immunity. Specifically, Dr. Sinha examined the lysosomal targeting property of lysosomal-associated membrane protein-1 (LAMP-1) in DNA vaccines to direct the model protein to MHCII pathway. Dr. Pratima Sinha will present her data and findings of tumor therapy models. LAMP-Vax™, Immunomic's exclusive technology platform, works with the body’s natural biochemistry and has the potential to complement a variety of immuno-modulatory therapies.
Who: Immunomic Therapeutics, Inc. Scientist Pratima Sinha, Ph.D.
What: Presentation at the 3rd Annual International Conference on Vaccine Research and Development: Lysosomal-Associated Membrane Protein-1-Targeting of Antigen for Increased Efficacy of DNA Vaccination.
When: Tuesday, November 14, 2017, Track B at 2-2:25 pm EST
Where: Sheraton Reston Hotel, 11810 Sunrise Valley Drive, Reston, VA 20191
About LAMP-Vax
ITI’s investigational LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put LAMP-Vax technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. LAMP is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of LAMP in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for LAMP-Vax therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, an immunotherapy platform, for use in the prevention and treatment of allergic diseases. For information about ITI and LAMP Technology, visit www.immunomix.com.
